个性化的多位纳米疫苗解锁了B细胞介导的抗瘤免疫的多种途径
Wenlu Yan1,2, Ying Cao1,3, Shanshan Xu4
1State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Advanced materials (Deerfield Beach, Fla.)
|December 23, 2024
概括
这项研究开发了一种新型纳米疫苗 (CM-CpG-aCD40),使用三阴性乳腺癌细胞膜激活B细胞并增强抗瘤免疫力. 纳米疫苗显著抑制了瘤的生长,提供了一个有前途的新免疫疗法.
科学领域:
- 免疫学 免疫学 免疫学
- 纳米技术纳米技术
- 在瘤学瘤学.
背景情况:
- B 淋巴细胞是癌症免疫调节的关键目标.
- 目前的瘤细胞膜疫苗缺乏足够的辅助刺激分子来实现最佳的B细胞激活.
- 三阴性乳腺癌对有效的免疫疗法提出了独特的挑战.
研究的目的:
- 设计一个时空同步的抗原辅助剂集成纳米疫苗 (CM-CpG-aCD40),以增强B细胞介导的抗瘤免疫力.
- 研究CM-CpG-aCD40在激活幽默,细胞和先天免疫反应中的机制.
- 评估CM-CpG-aCD40单独或与PD-L1阻断结合的治疗疗效,对抗三阴性乳腺癌.
主要方法:
- 构建CM-CpG-aCD40通过结合CpG寡核酸和抗CD40抗体,使三阴性乳腺癌细胞膜囊泡形成.
- 评估纳米疫苗在淋巴结中的积累和抗原呈现细胞的吸收.
- 评估B细胞激活,抗体分泌和抗原呈现能力.
- 对树突细胞激活,CD8+ T细胞反应和与瘤相关的巨细胞重编程的分析.
- 在体内有效性研究测量瘤抑制率.
主要成果:
- CM-CpG-aCD40显示了活性淋巴结积累和抗原呈现细胞的有效吸收.
- 纳米疫苗有效地刺激了B细胞,增强了它们的抗体分泌和抗原呈现功能.
- CM-CpG-aCD40诱导了强大的抗瘤免疫力,达到89.3%的瘤抑制率.
- 与抗PD-L1抗体的联合治疗进一步改善了瘤抑制的95.4%.
结论:
- CM-CpG-aCD40代表了一种新的,个性化的多位子纳米疫苗,可以协同激活抗瘤免疫系统的多个臂.
- 这种综合纳米疫苗策略克服了传统疫苗的局限性,通过提供必要的B细胞激活的共同刺激.
- CM-CpG-aCD40对推进基于B细胞的免疫疗法具有显著的前景,特别是在挑战癌症的组合疗法中,如三阴性乳腺癌.
更多相关视频
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
1.2K
08:09Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
Published on: March 24, 2017
9.4K
相关概念视频
Tumor Immunotherapy
475
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
475
Cancer Vaccines
338
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
338
Hybridoma Technology
14.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.1K
B Cell Activation and Differentiation
1.6K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.6K
